| FIS |
Report |
Q2 2026 revenue |
BEAT |
pred ~$3.42B vs. cons $3.38B |
MEDIUM |
| FIS |
Report |
Q2 2026 adjusted EBITDA |
BEAT |
pred ~$1.43B vs. cons $1.405B |
MEDIUM |
| FIS |
Report |
Q2 2026 adjusted EPS |
BEAT |
pred ~$1.50 vs. cons $1.47 |
MEDIUM |
| FIS |
Guide |
FY2026 adjusted revenue |
UNCHANGED |
guide ~$13.81B vs. cons $13.82B (FY2026) |
MEDIUM |
| FIS |
Guide |
FY2026 adjusted EBITDA |
UNCHANGED |
guide ~$5.83B vs. cons $5.84B (FY2026) |
MEDIUM |
| FIS |
Guide |
FY2026 adjusted EPS |
UNCHANGED |
guide ~$6.27 vs. cons $6.28 (FY2026) |
MEDIUM |
| FIS |
Guide |
FY2026 free cash flow |
UNCHANGED |
guide ~$2.10B vs. cons $2.10B (FY2026) |
MEDIUM |
| FIS |
Guide |
Total Issuing cost synergies |
UNCHANGED |
guide ~$35M vs. prior target midpoint $35M (FY2026) |
MEDIUM |
| FIS |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.0% |
— |
LOW |
| FIS |
Return |
5-day cumulative residual |
+0.5% (FADE) |
A modest Q2 beat can initially de-risk execution, but unchanged FY2026 guidance would imply ~$0.03 less second-half EPS versus pre-report consensus after absorbing the predicted Q2 beat, limiting upward revisions and causing most of the day-1 gain to fade. |
MEDIUM |